Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego W Lodzi SPZOZ
- Address
- lock Available on a paid plan
Cardiovascular and Heart Failure Research
At Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego W Lodzi SPZOZ, a major focus is cardiovascular disease and heart failure, with studies spanning acute and chronic forms of the condition as well as related kidney and inflammatory complications. This work is aimed at testing new treatment approaches and improving outcomes for people living with complex heart disease.
- Heart failure with preserved, mildly reduced, or reduced ejection fraction
- Acute myocardial infarction and atherosclerotic cardiovascular disease
- Cardiorenal disease, systemic inflammation, and treatment response
These trials explore whether new therapies can reduce hospitalizations, lower cardiovascular risk, and improve symptoms and heart function.
Kidney, Metabolic, and Inflammation-Linked Studies
Research at this hospital clinic also includes chronic kidney disease and conditions where kidney problems overlap with heart disease and high blood pressure. The studies are designed to evaluate whether emerging treatments can slow disease progression and better control inflammation-driven illness.
- Chronic kidney disease with hypertension or systemic inflammation
- Heart failure complicated by impaired kidney function
- Inflammation-related cardiovascular and renal risk
Overall, this area of research is focused on finding safer and more effective ways to protect both kidney and cardiovascular health.
Respiratory and Lung Disease Trials
The site contributes to respiratory disease research, especially in chronic obstructive pulmonary disease and progressive pulmonary fibrosis. These studies aim to assess whether new therapies can reduce worsening symptoms, limit flare-ups, and preserve lung function over time.
- Chronic obstructive pulmonary disease and chronic bronchitis
- Progressive pulmonary fibrosis
- Long-term symptom control and lung function preservation
This research supports the search for better treatment options in chronic lung conditions that can significantly affect daily life.
Immune-Mediated Skin and Muscle Disorders
Another important area is immune system disease, including inflammatory skin and muscle disorders. Trials here examine whether new therapies can improve disease control, reduce active inflammation, and support sustained remission in conditions that are often difficult to manage.
- Bullous pemphigoid
- Moderate-to-severe plaque psoriasis
- Polymyositis and dermatomyositis
These studies are focused on testing treatment effectiveness and helping patients achieve better symptom relief and disease stability.
Neurology and Musculoskeletal Care
Clinical research at the site also extends to nervous system diseases and musculoskeletal disorders, reflecting a broad interest in conditions that affect movement, strength, and long-term function. The studies are intended to evaluate new options that may slow progression or improve recovery and quality of life.
- Primary progressive multiple sclerosis
- Total knee arthroplasty and prevention of venous thromboembolism
- Musculoskeletal and neural functional outcomes
This line of research combines treatment innovation with practical goals such as better postoperative protection and improved disability management.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 11 therapeutic areas and 15 of 64 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 52 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 13 by active trials.
- 1AstraZeneca AB3active
lock +12 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +5 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 1 624 other sites in Poland
Therapeutic Area Benchmark — Poland
Select a therapeutic area to compare against other sites in Poland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Poland
Market Share
Country: Poland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Uniwersytecki Szpital Kliniczny Nr 2 Uniwersytetu Medycznego W Lodzi SPZOZ
lock Showing 1 of 35 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 3, Multicenter, Randomized, Open-Label, Sponsor-Blinded, Study to Evaluate REGN7508, A Factor XI Monoclonal Antibody, Versus Apixaban and Enoxaparin for Prophylaxis of Venous Thromboembolism After Elective Total Knee Arthroplasty (ROXI-APEX). | Regeneron Pharmaceuticals Inc. | Phase III | Recruiting | Nov 2025 | — |
IMP list
lock Showing 1 of 64 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Ziltivekimab | 4 | Unknown | 2021-09-24 | 2024-08-01 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.
